Peter G. Lawlor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter G. Lawlor has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Eduardo D. Bruera
2 shared publicationsBruno Gagnon
1 shared publication- Bruno Gagnon
Family physician, Associate Professor in the Department of Family Medicine and Emergency Medicine, and member of the Cancer Research Centre at Laval University in Quebec, as well as a palliative care consultant for the Centre intégré universitaire de santé et services sociaux de la Capitale-Nationale and at the CHU de Québec-Université Laval.
1 shared publication C Nekolaichuk
1 shared publicationE D Bruera
1 shared publication- E. Bruera
Department of Symptom Control and Palliative Care, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA
1 shared publication
Latest Publications
- 15 November 2000
- Published by American Medical Association (AMA) in JAMA
- Vol. 284 (19) , 2427-2429
Delirium at the End of Life
Delirium frequently complicates care at the end of life. Although usually described as a transient and potentially reversible disorder of cognition and attent
- 15 November 2000
- Published by American Medical Association (AMA) in JAMA
- Vol. 284 (19) , 2427-2429
Delirium at the End of Life
Delirium frequently complicates care at the end of life. Although usually described as a transient and potentially reversible disorder of cognition and attent
- 15 June 2000
- Vol. 88 (12) , 2859-67
Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: Assessing delirium in advanced cancer.
Delirium is a common neuropsychiatric complication in patients with advanced cancer. The Memorial Delirium Assessment Scale (MDAS) is a recently developed 10-item severity rating instrument. The purpose of the current prospective study was to further assess the clinical utility, factor structure, and validity of the MDAS in a relatively homogeneous population of patients with advanced cancer. Study entry of 104 patients occurred on their consecutive admission to a tertiary-level, acute palliative care unit in a university-affiliated teaching hospital. Patients underwent regular cognitive screening using the Mini-Mental State Examination, and serial monitoring of delirium using standardized semistructured interviews and MDAS ratings, up to the study endpoints of either patient discharge or death. Seventy-one patients met Diagnostic and Statistical Manual (of Mental Disorders)-IV criteria for a first episode of delirium. In 15 of 71 (21%) patients with a first episode of delirium, the first MDAS ratings were prorated because of dyspnea, fatigue, or profound delirium. In the remaining 56 patients (79%), the first MDAS ratings were rated fully and therefore evaluable. Correlations among the scale items ranged from moderate to low (correlation coefficient [r] = 0.68-0.02). Analysis of the pattern of factor loadings identified two primary correlated factors: global cognitive (Factor I) and neurobehavioral (Factor II) (r = 0.33). Cronbach alpha coefficients for Factors I and II were 0.8 and 0.66, respectively, indicating a relatively high level of correlation for items within each. The Cronbach alpha coefficient for all 10 items was 0.78, suggesting a general underlying factor. In a larger sample of complete MDAS ratings (n = 330) a cutoff total MDAS score of 7 of 30 yielded the highest sensitivity (98%) and specificity (96%) for delirium diagnosis. The MDAS was correlated moderately with the Mini-Mental State Examination (r = 0.55). The authors concluded that the MDAS structure is representative of the many features of delirium, broadly grouped as global cognitive and neurobehavioral dimensions. Prorating item scores is necessary in approximately 20% of advanced cancer patients with delirium. This poses potential limitations on the applicability of the MDAS in research. Conversely, the ability to prorate item scores confers a clinical advantage to the instrument when assessing delirium in a patient population with advanced cancer.
- 15 June 2000
- Vol. 88 (12) , 2859-67
Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer: Assessing delirium in advanced cancer.
Delirium is a common neuropsychiatric complication in patients with advanced cancer. The Memorial Delirium Assessment Scale (MDAS) is a recently developed 10-item severity rating instrument. The purpose of the current prospective study was to further assess the clinical utility, factor structure, and validity of the MDAS in a relatively homogeneous population of patients with advanced cancer. Study entry of 104 patients occurred on their consecutive admission to a tertiary-level, acute palliative care unit in a university-affiliated teaching hospital. Patients underwent regular cognitive screening using the Mini-Mental State Examination, and serial monitoring of delirium using standardized semistructured interviews and MDAS ratings, up to the study endpoints of either patient discharge or death. Seventy-one patients met Diagnostic and Statistical Manual (of Mental Disorders)-IV criteria for a first episode of delirium. In 15 of 71 (21%) patients with a first episode of delirium, the first MDAS ratings were prorated because of dyspnea, fatigue, or profound delirium. In the remaining 56 patients (79%), the first MDAS ratings were rated fully and therefore evaluable. Correlations among the scale items ranged from moderate to low (correlation coefficient [r] = 0.68-0.02). Analysis of the pattern of factor loadings identified two primary correlated factors: global cognitive (Factor I) and neurobehavioral (Factor II) (r = 0.33). Cronbach alpha coefficients for Factors I and II were 0.8 and 0.66, respectively, indicating a relatively high level of correlation for items within each. The Cronbach alpha coefficient for all 10 items was 0.78, suggesting a general underlying factor. In a larger sample of complete MDAS ratings (n = 330) a cutoff total MDAS score of 7 of 30 yielded the highest sensitivity (98%) and specificity (96%) for delirium diagnosis. The MDAS was correlated moderately with the Mini-Mental State Examination (r = 0.55). The authors concluded that the MDAS structure is representative of the many features of delirium, broadly grouped as global cognitive and neurobehavioral dimensions. Prorating item scores is necessary in approximately 20% of advanced cancer patients with delirium. This poses potential limitations on the applicability of the MDAS in research. Conversely, the ability to prorate item scores confers a clinical advantage to the instrument when assessing delirium in a patient population with advanced cancer.
- Top Cited PapersOpen Access
- 27 March 2000
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 160 (6) , 786-794
Occurrence, Causes, and Outcome of Delirium in Patients With Advanced Cancer
DELIRIUM IS one of the most common neuropsychiatric complications in patients with advanced cancer.1-6 The multiple synonyms used to describe this condition, eg, acute confusional state, terminal restlessness, or cognitive impairment, along with the variability in diagnostic criteria have hindered the conduct of research and the comparison of study findings.7-10 Delirium has been underrecognized and underresearched in general medical patients and patients with cancer.5,8,10 In patients with advanced cancer, delirium imposes an additional burden of symptom distress, as the consequent awareness and attentional deficits impede communication with their families and hinder participation in treatment decisions, counseling, and symptom assessment.10-13 Delirium reversibility in advanced cancer has been the subject of much debate5,6,13,14 but relatively limited research, mainly as retrospective studies15-18 or case reports19,20 and in the form of only a few prospective studies.1,2,21-23 The cause of delirium in advanced cancer is often multifactorial,5 but since 1990 there have been increasing literature reports on delirium and other neuropsychiatric side effects of opioids in patients with cancer.24-26 Previous studies in patients with cancer have not incorporated a standardized or systematic approach to criteria for analysis of precipitating factors similar to that used in the study of elderly hospitalized general medical patients.27
- 27 March 2000
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 160 (6) , 786-794
Top Cited PapersOpen AccessOccurrence, Causes, and Outcome of Delirium in Patients With Advanced Cancer
DELIRIUM IS one of the most common neuropsychiatric complications in patients with advanced cancer.1-6 The multiple synonyms used to describe this condition, eg, acute confusional state, terminal restlessness, or cognitive impairment, along with the variability in diagnostic criteria have hindered the conduct of research and the comparison of study findings.7-10 Delirium has been underrecognized and underresearched in general medical patients and patients with cancer.5,8,10 In patients with advanced cancer, delirium imposes an additional burden of symptom distress, as the consequent awareness and attentional deficits impede communication with their families and hinder participation in treatment decisions, counseling, and symptom assessment.10-13 Delirium reversibility in advanced cancer has been the subject of much debate5,6,13,14 but relatively limited research, mainly as retrospective studies15-18 or case reports19,20 and in the form of only a few prospective studies.1,2,21-23 The cause of delirium in advanced cancer is often multifactorial,5 but since 1990 there have been increasing literature reports on delirium and other neuropsychiatric side effects of opioids in patients with cancer.24-26 Previous studies in patients with cancer have not incorporated a standardized or systematic approach to criteria for analysis of precipitating factors similar to that used in the study of elderly hospitalized general medical patients.27
- 15 March 1998
- Vol. 82 (6) , 1167-73
Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.
Current equianalgesic reference tables, based largely on single dose studies, give dose ratios of 1:1 to 4:1 for oral morphine to oral methadone, which possibly are inaccurate in patients with cancer pain who are exposed to multiple doses of these opioids. The purpose of this study was to determine the equianalgesic dose ratio between morphine and methadone in patients with cancer pain and to establish whether the dose ratio changes as a function of previous opioid dose. A retrospective analysis of consecutive rotations involving morphine and methadone using standard selection criteria identified a total of 20 evaluable rotations (14 from morphine to methadone and 6 from methadone to morphine). Opioid doses and pain intensity levels pre- and postrotation were analyzed. Median dose ratios (lower-upper quartiles) for morphine to methadone and methadone to morphine rotations were 11.36 (range, 5.98-16.27) and 8.25 (range, 4.37-11.3), respectively (P = 0.23). Combining all 20 rotations, a unified median dose ratio of 11.2 (range, 5.06-13.24) was calculated. There was no significant difference in pain intensity levels pre- and postrotation as recorded on a visual analogue scale. Univariate correlational analysis of dose ratio and the level of daily morphine dose prior to rotation revealed a Spearman correlation coefficient of 0.86 (P = 0.0001). In patients receiving >1165 mg per day prior to methadone rotation, a median dose ratio of 16.84 (range, 12.25-87.95) was observed, which was approximately 3 times higher compared with a median dose ratio of 5.42 (range, 2.95-9.09) (P = 0.007) for the 50% of patients receiving lower morphine doses. The results highlight the general underestimation of methadone potency and the consequent risk of potential life-threatening toxicity. The strongly positive correlation between dose ratio and previous morphine dose suggests the need for a highly individualized and cautious approach when rotating from morphine to methadone in patients with cancer pain.
- 15 March 1998
- Vol. 82 (6) , 1167-73
Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study.
Current equianalgesic reference tables, based largely on single dose studies, give dose ratios of 1:1 to 4:1 for oral morphine to oral methadone, which possibly are inaccurate in patients with cancer pain who are exposed to multiple doses of these opioids. The purpose of this study was to determine the equianalgesic dose ratio between morphine and methadone in patients with cancer pain and to establish whether the dose ratio changes as a function of previous opioid dose. A retrospective analysis of consecutive rotations involving morphine and methadone using standard selection criteria identified a total of 20 evaluable rotations (14 from morphine to methadone and 6 from methadone to morphine). Opioid doses and pain intensity levels pre- and postrotation were analyzed. Median dose ratios (lower-upper quartiles) for morphine to methadone and methadone to morphine rotations were 11.36 (range, 5.98-16.27) and 8.25 (range, 4.37-11.3), respectively (P = 0.23). Combining all 20 rotations, a unified median dose ratio of 11.2 (range, 5.06-13.24) was calculated. There was no significant difference in pain intensity levels pre- and postrotation as recorded on a visual analogue scale. Univariate correlational analysis of dose ratio and the level of daily morphine dose prior to rotation revealed a Spearman correlation coefficient of 0.86 (P = 0.0001). In patients receiving >1165 mg per day prior to methadone rotation, a median dose ratio of 16.84 (range, 12.25-87.95) was observed, which was approximately 3 times higher compared with a median dose ratio of 5.42 (range, 2.95-9.09) (P = 0.007) for the 50% of patients receiving lower morphine doses. The results highlight the general underestimation of methadone potency and the consequent risk of potential life-threatening toxicity. The strongly positive correlation between dose ratio and previous morphine dose suggests the need for a highly individualized and cautious approach when rotating from morphine to methadone in patients with cancer pain.